Alpha 2.0
Login Register
» Authors » Donald L Heald

Donald L Heald

Explore the profile of Donald L Heald including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 114
Followers 0
Related Specialties
Pharmacology
Allergy & Immunology
Neurology
Top 10 Co-Authors
Thomas J Carpenter
Christopher R Curtin
Weirong Wang
Alice Zong
Shean-Sheng Wang
Prasarn Manitpisitkul
Kevin Shalayda
Xirong Zheng
Wenbo Chen
Lisa Ford
Published In
MAbs
Clin Drug Investig
Clin Pharmacol Ther
Epilepsy Res
CPT Pharmacometrics Syst Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of -Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
Ayyar V, Song D, Zheng S, Carpenter T, Heald D
J Pharmacol Exp Ther . 2021 Aug; 379(2):134-146. PMID: 34413198
Conjugation of small interfering RNA (siRNA) to tris -acetylgalactosamine [(GalNAc)] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver. However, potential knowledge gaps between in...
2.
Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T
Singh A, Chen W, Zheng X, Mody H, Carpenter T, Zong A, et al.
CPT Pharmacometrics Syst Pharmacol . 2021 Feb; 10(4):362-376. PMID: 33565700
Despite tremendous success of chimeric antigen receptor (CAR) T cell therapy in clinical oncology, the dose-exposure-response relationship of CAR-T cells in patients is poorly understood. Moreover, the key drug-specific and...
3.
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
Singh A, Zheng X, Lin-Schmidt X, Chen W, Carpenter T, Zong A, et al.
MAbs . 2019 Dec; 12(1):1688616. PMID: 31852337
The development of mechanism-based, multiscale pharmacokinetic-pharmacodynamic (PK-PD) models for chimeric antigen receptor (CAR)-T cells is needed to enable investigation of and correlation of CAR-T cell responses and to facilitate preclinical-to-clinical...
4.
Geriatrics 2030: Developing Drugs to Care for Older Persons-A Neglected and Growing Population
Lau S, Schlender J, Slattum P, Heald D, OConnor-Semmes R
Clin Pharmacol Ther . 2019 Nov; 107(1):53-56. PMID: 31667834
No abstract available.
5.
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
Jiang X, Chen X, Carpenter T, Wang J, Zhou R, Davis H, et al.
MAbs . 2018 Jul; 10(6):876-889. PMID: 29985776
T-cell redirecting bispecific antibodies (bsAbs) or antibody-derived agents that combine tumor antigen recognition with CD3-mediated T cell recruitment are highly potent tumor-killing molecules. Despite the tremendous progress achieved in the...
6.
Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment
Manitpisitkul P, Curtin C, Shalayda K, Wang S, Ford L, Heald D
Epilepsy Res . 2014 Apr; 108(5):891-901. PMID: 24725807
Purpose: Topiramate is primarily renally excreted. Chronic renal and hepatic impairment can affect the clearance of topiramate. Therefore, the objective was to establish dosage guidelines for topiramate in chronic renal...
7.
An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus
Manitpisitkul P, Curtin C, Shalayda K, Wang S, Ford L, Heald D
Clin Drug Investig . 2013 Oct; 33(12):929-38. PMID: 24132772
Background: Topiramate is approved for epilepsy and migraine headache management and has potential antidiabetic activity. Because topiramate and antidiabetic drugs may be co-administered, the potential drug-drug interactions between topiramate and...